Cited by 7,205Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment ApproachesInfective Endocarditis Diagnosis and Management

Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery

Open access
Leon, Martin B., Smith, Craig R., Mack, Michael, Miller, D. Craig, Moses, Jeffrey W., Svensson, Lars G., Tuzcu, E. Murat, Webb, John G. +14 more·2010·New England Journal of Medicine

Abstract

BACKGROUND: Many patients with severe aortic stenosis and coexisting conditions are not candidates for surgical replacement of the aortic valve. Recently, transcatheter aortic-valve implantation (TAVI) has been suggested as a less invasive treatment for high-risk patients with aortic stenosis. METHODS: We randomly assigned patients with severe aortic stenosis, whom surgeons considered not to be suitable candidates for surgery, to standard therapy (including balloon aortic valvuloplasty) or transfemoral transcatheter implantation of a balloon-expandable bovine pericardial valve. The primary end point was the rate of death from any cause. RESULTS: A total of 358 patients with aortic stenosis who were not considered to be suitable candidates for surgery underwent randomization at 21 centers (17 in the United States). At 1 year, the rate of death from any cause (Kaplan–Meier analysis) was 30.7% with TAVI, as compared with 50.7% with standard therapy (hazard ratio with TAVI, 0.55; 95% confidence interval [CI], 0.40 to 0.74; P<0.001). The rate of the composite end point of death from any cause or repeat hospitalization was 42.5% with TAVI as compared with 71.6% with standard therapy (hazard ratio, 0.46; 95% CI, 0.35 to 0.59; P<0.001). Among survivors at 1 year, the rate of cardiac symptoms (New York Heart Association class III or IV) was lower among patients who had undergone TAVI than among those who had received standard therapy (25.2% vs. 58.0%, P<0.001). At 30 days, TAVI, as compared with standard therapy, was associated with a higher incidence of major strokes (5.0% vs. 1.1%, P=0.06) and major vascular complications (16.2% vs. 1.1%, P<0.001). In the year after TAVI, there was no deterioration in the functioning of the bioprosthetic valve, as assessed by evidence of stenosis or regurgitation on an echocardiogram. CONCLUSIONS: In patients with severe aortic stenosis who were not suitable candidates for surgery, TAVI, as compared with standard therapy, significantly reduced the rates of death from any cause, the composite end point of death from any cause or repeat hospitalization, and cardiac symptoms, despite the higher incidence of major strokes and major vascular events. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1008232

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For patients at high or prohibitive risk of operative mortality with surgical aortic valve replacement, TAVR has been a transformative and life-saving treatment for those previously not candidates.

    “For patients at high or prohibitive risk of operative mortality, with surgical AVR, TAVR has been a transformative innovation, providing a life-saving treatment for patients who were previously not candidates for AVR”

    From Calcific aortic stenosis (2016) · cites this paper as [201]

    The Results (p. 1) show that TAVI reduced one-year mortality compared with standard therapy among patients who were not suitable candidates for surgery, supporting the life-saving characterization for that group. The Discussion (p. 10) explicitly says these results cannot be extrapolated to other patients and calls for trials in high-risk patients for whom surgery remains a viable option; this paper therefore does not establish the claim for that broader group. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Balloon-expandable and self-expanding transcatheter valves, specifically CoreValve and SAPIEN, have been the most rigorously studied to date.

    “Balloon-expandable and self-expanding transcatheter valves have been the most rigorously studied to date, specifically the CoreValve (Medtronic, Dublin, Ireland) and SAPIEN (Edwards, Irvine CA, USA) valves”

    From Calcific aortic stenosis (2016) · cites this paper as [201]

    The Study Device and Procedure section (p. 3) identifies SAPIEN as balloon-expandable, and the paper reports a randomized trial using it. The References (p. 11) identify CoreValve as self-expanding, but the paper does not establish that CoreValve and SAPIEN were the most rigorously studied valves. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In general, TAVR is associated with a survival advantage compared with conservative management without aortic valve replacement.

    “Although, in general, TAVR is associated with a survival advantage compared to conservative (no AVR) management”

    From Calcific aortic stenosis (2016) · cites this paper as [201]

    The Rates of Death section (p. 6) reports lower one-year mortality with TAVI than with standard therapy in patients unsuitable for surgery (30.7% versus 50.7%). The Discussion (p. 10) explicitly says these results cannot be extrapolated to other patients with aortic stenosis, so the source does not support the claim's unqualified “in general” framing. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Among inoperable patients treated with TAVR in PARTNER I Cohort B, at 1 year approximately 31% were dead and 18% had less than moderate improvement in quality of life or NYHA functional class.

    “among inoperable patients treated with TAVR in the PARTNER I Cohort B trial (Table 4), at 1 year after the procedure approximately 31% were dead and 18 % had less than a moderate improvement in their quality of life or New York Heart Association functional class201;244”

    From Calcific aortic stenosis (2016) · cites this paper as [201]

    The Results (p. 1) report 30.7% mortality at one year in the TAVI group, supporting the approximately 31% figure. Other Clinical Outcomes (p. 6) report that 74.8% of surviving TAVI patients were in NYHA class I or II, but do not report that 18% had less than moderate improvement in quality of life or NYHA class. (LLM, conf=0.89)

    Experimental — accuracy not yet measured
  • A sizable subgroup dies soon after TAVR or does not experience improved quality of life, suggesting potential futility of TAVR in some patients.

    “there is a sizable sub-group that dies soon after TAVR or does not experience an improvement in quality of life, suggesting potential futility of TAVR in some patients201;202;220;244;245.”

    From Calcific aortic stenosis (2016) · cites this paper as [201]

    Procedural Outcomes (p. 4) reports that 11 of 173 patients who underwent TAVI (6.4%) died within 30 days; Results (p. 1) reports 30.7% mortality at one year. Other Clinical Outcomes (p. 6) reports improved symptoms overall, but does not establish a subgroup whose quality of life failed to improve. The paper does not assess futility in such a subgroup. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [17]17. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD Jr, Gualano SK. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. Circ Cardiovasc Qual Outcomes 2009;2:533-9.
  2. [36]36. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 2002;166:111-7.
  3. [37]37. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999; 18:1341-54.

Cited by

Sorted by citations

Authors
Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., Brown, D. L., Block, P. C., Guyton, R. A., Pichard, A. D., Bavaria, J. E., Herrmann, H. C., Douglas, P. S., Petersen, J. L., Akin, J. J., Anderson, W. N., Wang, D., & Pocock, S.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • Medical City Dallas Hospital (US)
  • Stanford Medicine (US)
  • Cleveland Clinic (US)
  • University of British Columbia (CA)
  • Cedars-Sinai Medical Center (US)
  • Emory University (US)
  • MedStar Washington Hospital Center (US)
  • Hospital of the University of Pennsylvania (US)
  • Duke Medical Center (US)
  • Edwards Lifesciences (United States) (US)
  • London School of Hygiene & Tropical Medicine (GB)
Venue
New England Journal of Medicine
Published
2010-10-21
Volume
363
Issue
17
Pages
1597-1607
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2149609916
Cited by
7,205
References
43
Citations by year
2026: 226 · 2025: 309 · 2024: 312 · 2023: 349 · 2022: 374 · 2021: 410 · 2020: 462 · 2019: 521 · 2018: 503 · 2017: 565 · 2016: 555 · 2015: 570 · 2014: 511 · 2013: 580 · 2012: 569
FWCI
335.24
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Epidemiology › Infective Endocarditis Diagnosis and Management
Keywords
transcatheter aortic valve implantation, severe aortic stenosis, inoperable patients, bovine pericardial valve, transfemoral access, balloon aortic valvuloplasty, all-cause mortality, stroke, vascular complications, cardiac symptoms, high-risk surgical patients, bioprosthetic valve durability, recurrent hospitalization
MeSH terms
Aged, Aged, 80 and over, Aortic Valve Stenosis, Cardiovascular Diseases, Catheterization, Echocardiography, Female, Cardiac Catheterization, Hospitalization, Humans, Male, Prospective Studies, Treatment Outcome, Heart Valve Prosthesis Implantation, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review